Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.

[1]  U. Galili.  Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody , 2004, Springer Seminars in Immunopathology.

[2]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[3]  H. Maguire,et al.  Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. , 2001, International journal of cancer.

[4]  H. Preisler,et al.  Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes , 2001 .

[5]  M. Tanemura,et al.  Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris , 2001 .

[6]  M. Tanemura,et al.  Differential expression of alpha-GAL epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on pig and mouse organs. , 2000, Transplantation.

[7]  S. Y. Zhang,et al.  Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. , 1999, Cancer research.

[8]  G. Ayala,et al.  Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. , 1998, Transplantation.

[9]  M. Radic,et al.  A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. , 1998, Transplantation.

[10]  A. Houghton,et al.  Fc receptors are required in passive and active immunity to melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  U. Galili,et al.  Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. , 1997, Immunology today.

[12]  W. Hauck,et al.  Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Hans Hengartner,et al.  Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity , 1997, Immunological reviews.

[14]  L. Old.  Immunotherapy for cancer. , 1996, Scientific American.

[15]  T. Tedder,et al.  Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. , 1996, Journal of immunology.

[16]  U. Galili,et al.  Synthesis of α-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opsonization of Human Tumor Cell Vaccines by Anti-Galactose , 1996 .

[17]  A. Lanzavecchia,et al.  Mechanisms of antigen uptake for presentation. , 1996, Current opinion in immunology.

[18]  G. Maass,et al.  Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Groth,et al.  Anti‐Gal activity In diabetic patients transplanted with fetal porcine Islet cell clusters , 1995, Transplantation.

[20]  J. Platt,et al.  Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. , 1995, Journal of immunology.

[21]  S. Beissert,et al.  Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.

[22]  F. Reinholt,et al.  Transplantation of porcine fetal pancreas to diabetic patients , 1994, The Lancet.

[23]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[24]  U. Galili,et al.  Defining the minimal size of catalytically active primate alpha 1,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme. , 1994, Glycobiology.

[25]  U. Galili.  Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. , 1993, Immunology today.

[26]  G. Nossal.  Tolerance and Ways to Break It a , 1993, Annals of the New York Academy of Sciences.

[27]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[28]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[29]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[30]  P. Livingston.  Active Specific Immunotherapy in the Treatment of Patients with Cancer , 1991, Immunology and Allergy Clinics of North America.

[31]  T. Bieber,et al.  Human epidermal Langerhans cells express only the 40-kilodalton Fc gamma receptor (FcRII). , 1990, Journal of immunology.

[32]  P. Coulie,et al.  Antitumor Lymphocyte-t Responses , 1990 .

[33]  J. Unkeless.  Function and heterogeneity of human Fc receptors for immunoglobulin G. , 1989, The Journal of clinical investigation.

[34]  S. Shohet,et al.  Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. , 1988, The Journal of biological chemistry.

[35]  J. Griffiss,et al.  Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora , 1988, Infection and immunity.

[36]  S. Shohet,et al.  Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Shohet,et al.  The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies , 1987, The Journal of experimental medicine.

[38]  S. Shohet,et al.  Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues , 1985, The Journal of experimental medicine.

[39]  U. Galili,et al.  A Unique Natural Human Igg Antibody with Anti-a-galactosyl Specificity , 2022 .

[40]  L. A. Murphy,et al.  Immunochemical studies of the combining sites of the two isolectins, A4 and B4, isolated from Bandeiraea simplicifolia. , 1979, Archives of biochemistry and biophysics.

[41]  J. Roboz,et al.  Specific immunotherapy with neuraminidase-modified leukemic cells: experimental and clinical trials. , 1977, The Medical clinics of North America.

[42]  J. Roboz,et al.  THERAPEUTIC EFFECTIVENESS OF NEURAMINIDASE‐TREATED TUMOR CELLS AS AN IMMUNOGEN IN MAN AND EXPERIMENTAL ANIMALS WITH LEUKEMIA * , 1976, Annals of the New York Academy of Sciences.